EGFR-TKIs Pose Highest Cardiovascular Risk Among Tyrosine Kinase Inhibitors, Meta-Analysis Finds
核心洞察
A systematic review and meta-analysis of 25 RCTs encompassing 9,068 patients found TKI therapy significantly increases major adverse cardiovascular events (搜索) (OR = 2.13; 95% CI, 1.11–4.07; P = 0.02).
EGFR (搜索)-targeted TKIs carried the highest cardiotoxicity risk, with significantly elevated odds of arrhythmias (OR = 8.71), QT prolongation (搜索) (OR = 6.64), and cardiovascular adverse events overall (OR = 5.87).
VEGFR (搜索)-TKIs provided the greatest progression-free survival improvement (HR = 0.64), followed by EGFR (搜索)-TKIs (HR = 0.87) and PDGFR (搜索)-TKIs (HR = 0.68), while c-Kit (搜索) TKIs showed no significant PFS benefit.
A comprehensive systematic review and meta-analysis published in Frontiers in Pharmacology has revealed that tyrosine kinase inhibitors (TKIs) significantly elevate the risk of major adverse cardiovascular events (搜索) (MACE), with epidermal growth factor receptor inhibitors (EGFR (搜索)-TKIs) demonstrating the most pronounced cardiotoxicity profile among the four major target classes examined.
The analysis, encompassing 25 randomized controlled trials and 9,068 patients, found that TKI-treated patients faced more than double the risk of MACE compared with placebo (OR = 2.13; 95% CI, 1.11–4.07; P = 0.02). The findings underscore a critical tension in oncology: the same agents that meaningfully extend progression-free survival also carry substantial cardiovascular liabilities that demand careful clinical management.
EGFR (搜索)-TKIs Emerge as the Highest-Risk Class
Subgroup analysis by drug target revealed a striking hierarchy of cardiovascular risk. EGFR (搜索)-TKIs — including gefitinib, erlotinib, vandetanib, and osimertinib — were associated with the highest risk of MACE (OR = 2.68; 95% CI, 1.01–7.10; P = 0.05). In contrast, VEGFR (搜索)-TKIs, PDGFR (搜索)-TKIs, and c-Kit (搜索) TKIs did not show statistically significant associations with the three-point MACE composite, which comprises non-fatal myocardial infarction, non-fatal stroke, and cardiovascular mortality.
When the analysis was broadened to include all cardiovascular adverse events (CVAEs), the risk gradient persisted: EGFR (搜索)-TKIs carried the highest risk (OR = 5.87; 95% CI, 3.73–9.23; P < 0.00001), followed by VEGFR (搜索)-TKIs (OR = 2.35), PDGFR (搜索)-TKIs (OR = 1.62), and c-Kit (搜索) TKIs (OR = 1.56).
For specific adverse events, EGFR (搜索)-TKIs demonstrated an OR of 8.71 (95% CI, 4.43–17.13; P < 0.00001) for arrhythmias and an OR of 6.64 (95% CI, 3.96–11.14; P < 0.00001) for QT prolongation (搜索). Hypertension (搜索) risk was highest with PDGFR (搜索)-TKIs (OR = 6.23; 95% CI, 4.92–7.90; P < 0.00001), followed by VEGFR (搜索)-TKIs (OR = 5.83; 95% CI, 4.71–7.21; P < 0.00001).
The Single-Target Paradox
A counterintuitive finding emerged when comparing single-target and multi-target TKIs: single-target agents, which in this analysis were exclusively EGFR (搜索)-TKIs, were associated with a significantly higher MACE risk (OR = 2.68; P = 0.05), while multi-target TKIs showed no significant difference from placebo.
The authors propose several explanations. EGFR (搜索) is not only expressed in tumor cells but also plays essential physiological roles in cardiomyocytes and vascular endothelium. "Inhibition of EGFR by EGFR-TKIs disrupts these protective pathways, leading to reduced nitric oxide bioavailability, increased oxidative stress, and impaired calcium handling in cardiac myocytes," the researchers note. "These molecular disturbances manifest clinically as QT interval prolongation, decreased left ventricular ejection fraction, and heightened susceptibility to arrhythmias."
In contrast, multi-target TKIs inhibit several kinases simultaneously, which may activate compensatory mechanisms that partially offset cardiac effects. The authors also caution that differential surveillance — with EGFR (搜索)-TKIs receiving more rigorous cardiac monitoring due to their well-recognized QT prolongation (搜索) risk — may contribute to higher reported event rates.
Efficacy Analysis: VEGFR (搜索)-TKIs Lead in PFS Benefit
On the efficacy side, TKI therapy significantly prolonged progression-free survival compared with placebo (HR = 0.59; 95% CI, 0.45–0.75; P < 0.0001). Subgroup analysis by target revealed that VEGFR (搜索)-TKIs provided the greatest PFS improvement (HR = 0.64; 95% CI, 0.58–0.71), followed by EGFR (搜索)-TKIs (HR = 0.87; 95% CI, 0.79–0.96) and PDGFR (搜索)-TKIs (HR = 0.68; 95% CI, 0.59–0.79). c-Kit (搜索) TKIs showed no significant PFS benefit.
No significant difference in overall survival was observed between TKI and placebo groups (HR = 1.00; 95% CI, 0.92–1.08; P = 0.93), a finding the authors attribute to subsequent therapies received after trial periods and the dilution of cancer-specific mortality within all-cause survival data.
Tumor-Type Stratification Confirms Consistent Risk
Exploratory subgroup analysis comparing NSCLC trials with other solid tumor studies confirmed that increased CVAE risk was consistently observed across tumor types. EGFR (搜索)-TKIs maintained their position as the highest-risk class regardless of malignancy, suggesting the cardiotoxicity signal is driven by target pharmacology rather than disease-specific factors.
Clinical Implications and Limitations
The study, registered with PROSPERO (CRD420251084805), searched PubMed, Cochrane Library, Embase, WanFang Data, and CNKI from inception to June 2026. The authors acknowledge several limitations, including substantial heterogeneity in some analyses, reliance on investigator-reported adverse events rather than blinded cardiology adjudication, and the inability to analyze dose-dependent effects due to the lack of equivalent dose conversions across agents.
"These findings highlight the importance of considering each patient's cardiovascular profile when selecting a TKI," the authors conclude. "The choice of TKI should balance oncologic efficacy against the observed class-specific cardiovascular risks, and routine cardiac monitoring should be considered for all patients receiving high-risk agents."